Tag: Ibd treatment

Affecting as many as 1.25 million people in the United States, ulcerative colitis is a chronic inflammatory condition. A primary treatment for this condition is an anti-inflammatory drug, but what is mesalamine and how does it help manage the disease?

Ulcerative colitis (UC) affects as many as 900,000 people in the United States [1.7.3]. For many, a key goal is maintaining remission, and a significant question is, **what is Dipentum used for?** This medication is primarily prescribed to maintain remission of ulcerative colitis in adults [1.2.1, 1.4.3].

Approved by the FDA in October 2023, Zymfentra is the first and only subcutaneous formulation of infliximab available for maintenance treatment of inflammatory bowel disease (IBD). This innovative medication offers a new pathway for adult patients with moderate to severe Crohn’s disease or ulcerative colitis, providing a convenient, at-home option for long-term therapy.

In a randomized controlled study, 70% of patients with moderately active ulcerative colitis (UC) achieved treatment success with a high dose of mesalamine. When evaluating treatments for inflammatory bowel disease (IBD), patients often question: are biologics better than mesalamine?